Jessica Grossman, MD is the CEO of Medicines360, a global, non-profit pharmaceutical company dedicated to expanding access to medicines for women regardless of their socioeconomic status, insurance status or geographic location.
As CEO of Medicines360, she is dedicated to reducing the global disparity in the number of unplanned pregnancies and increasing access to highly effective contraception through the recent FDA-approval of Liletta®, the first low cost progestin intra-uterine device.
Dr. Grossman is an obstetrician-gynecologist by training and a social entrepreneur with a proven track record leading successful women’s health companies and improving the lives of countless women, particularly those with lower incomes, without insurance and the developing world.
As a medical technology executive, she brings a wealth of experience in product development, patient access, commercialization and the ability to accelerate profitable business models. Prior to joining Medicines360, Dr. Grossman served as founding president and CEO of Sense4Baby, Inc. where she closed a series A investment within 18 months of joining the organization, led the company to a successful acquisition following FDA clearance, CE mark and early commercialization.
Some of Dr. Grossman’s notable achievements include being founder and president of Gynesonics, an early stage medical device company focused on minimally invasive solutions for women’s health where she raised over $22 million in venture capital financing. Under her leadership, she developed the first intrauterine ultrasound guided radiofrequency ablation device for fibroid tumors.
She has also been a medical director at Ethicon Endo-Surgery, part of the Johnson and Johnson family of companies. Dr. Grossman also holds numerous patents and has published several peer reviewed articles.
She earned her MD degree at Thomas Jefferson University and graduated with honors from Brandeis University for her undergraduate degree. She also performed research at the Beth Israel Deaconess Medical Center, one of the teaching hospitals of Harvard Medical School.
Dr. Grossman has been a board member of Medicines360 since 2011. She can speak to the topics of drug pricing and patient access, women’s health, reproductive rights and family planning, global health disparities and patient equality, NGO and public-private partnerships.